Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

Simone Fulda

doi:10.18632/oncotarget.277

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

Simone Fulda _

PDF | HTML | How to cite

Oncotarget. 2011; 2:418-421. https://doi.org/10.18632/oncotarget.277

Metrics: PDF 2733 views | HTML 3643 views | ?

Abstract

Simone Fulda

¹Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany

Keywords: cancer, apoptosis, chemotherapy, proteasome inhibitor, TRAIL

Received: April 19, 2011; Accepted: May 14, 2011; Published: May 16, 2011;

Correspondence:

Simone Fulda, e-mail:

Abstract

The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing over the last years. A recent study identifies a new mechanism of action for the synergism of TRAIL and Bortezomib.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 277

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Perspectives:

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

Abstract